Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Loss Per Share

The following is a calculation of the basic and diluted net loss per share (in thousands, except share and per share data):

	Years ended December 31,
	2025		2024		2023
Net loss attributable to Vir Bio	$	(437,987)	$	(521,960)	$	(615,061)
Weighted-average shares outstanding, basic and diluted	138,520,419		136,246,865		134,130,924
Net loss per share attributable to Vir Bio, basic and diluted	$	(3.16)	$	(3.83)	$	(4.59)

Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations

Securities that could potentially dilute basic net loss per common share in the future that were not included in the computation of diluted net loss per common share because to do so would have been antidilutive for the years presented were as follows:

	Years ended December 31,
	2025	2024	2023
Options issued and outstanding	8,634,511	9,605,591	11,124,181
Restricted shares subject to future vesting	5,690,008	4,981,082	5,260,229
Total	14,324,519	14,586,673	16,384,410